Business Wire24d
Circle Pharma Announces First Patients Dosed in Phase 1 Clinical Trial of First-in-Class Oral Cyclin A/B RxL Inhibitor CID-078 for Advanced Solid Tumors
Until now there hasn’t been a selective therapeutic agent to exploit this observation and so I am extremely excited to see Circle Pharma’s cyclin A/B RxL inhibitor move into the clinic." ...
VentureBeat16d
Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium
Poster presentation details are below: Author: Wang et al. Title: CID-078, a First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, Demonstrates Anti-Tumor Activity in ESF-driven Cancers ...
Medscape25d
Exendin-4 Stimulation of Cyclin A2 in B-Cell Proliferation
Kornfeld; Fredric E. Wondisford; Mehboob A. Hussain siRNA transfection achieved ∼40% knockdown of cyclin A2 protein(Fig. 5). This resulted in a significantly reduced Min6 proliferation rate (1. ...
Nature3y
The classical and minimal models of cell cycle control
Cyclin-dependent kinases (CDKs) trigger the transition from G1 to S phase and from G2 to M phase by phosphorylating distinct sets of substrates. (B) CDK1 and CDK2 bind to multiple cyclins (cyclin ...
Business Wire1mon
Boehringer Ingelheim and Circle Pharma Announce New Research Collaboration to Develop a Novel Precision Cancer Treatment
David Earp, Ph.D., JD, chief executive officer, Circle Pharma said, “With our lead program, CID-078, a Cyclin A/B RxL inhibitor, we have demonstrated the capability of our MXMO TM platform to ...
News Medical on MSN9h
Traditional Chinese herb shows promise against Alzheimer’s and Parkinson’s
Zizyphi spinosi semen demonstrates neuroprotective effects, improving cognitive function and reducing amyloid and tau ...
Hosted on MSN29d
Boehringer and Circle Pharma link to develop new cancer treatment
Boehringer Ingelheim and Circle Pharma have entered a new research partnership and licence agreement to develop a new precision cancer treatment. The partnership aims to create a first-in-class ...
ascopubs.org23d
Cyclin-Dependent Kinase 4/6 Inhibition as a Novel Therapy for Peritoneal Mucinous Carcinomatosis With GNAS Mutations
Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia We enrolled 16 patients ...
Business Insider1d
Monte Rosa Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update
CDK2 and Cyclin E1-directed MGD programs In October ... VAV1, a Rho-family guanine nucleotide exchange factor, is a key signaling protein downstream of both the T- and B-cell receptors. VAV1 ...
Joplin Globe16d
Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium
CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation.
Circle Pharma’s First-in-Class Oral Macrocycle Cyclin A/B RxL Inhibitor, CID-078, Preclinical Data Highlighted at the 36th EORTC-NCI-AACR Symposium
Circle Pharma, a clinical-stage biopharmaceutical company dedicated to discovering and developing a new generation of macrocycle therapies, today announced that preclinical data from its lead ...